nach oben

Pediatric Cardiology

Erschienen in:

01.10.2009 | Review

Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients

verfasst von: Alice J. Huddleston, Chad A. Knoderer, Jennifer L. Morris, Eric S. Ebenroth

Erschienen in: Pediatric Cardiology | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Sildenafil is a phosphodiesterase 5 inhibitor widely used for the treatment of pulmonary hypertension in children. Despite limited available safety and efficacy evidence, use of sildenafil continues to increase. To date, sildenafil use for pediatric pulmonary hypertension has been characterized for 193 children through 16 studies and 28 case series and reports. The primary efficacy data suggest that sildenafil is beneficial for facilitating the weaning of inhaled nitric oxide in children after cardiac surgery. Compiled safety data suggest that sildenafil is well tolerated among children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. This review summarizes the available data describing the use, safety, and efficacy of sildenafil for children with pulmonary hypertension.

Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4PubMedCrossRef

Al-Khaldi A, Reitz BA, Zhu H, Rosenthal D (2006) Heterotopic heart transplant combined with postoperative sildenafil use for the treatment of restrictive cardiomyopathy. Ann Thorac Surg 81:1505–1507PubMedCrossRef

Antoniu SA (2006) Sildenafil citrate for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 7:825–828PubMedCrossRef

Atz AM, Wessel DL (1999) Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91:307–310PubMedCrossRef

Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124:628–629PubMedCrossRef

Baquero H, Soliz A, Neira F, Venegas ME, Sola A (2006) Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117:1077–1083PubMedCrossRef

Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121:409–415PubMed

Bentlin MR, Saito A, De Luca AK, Bossolan G, Bonatto RC, Martins AS, Rugolo LM (2005) Sildenafil for pulmonary hypertension treatment after cardiac surgery. J Pediatr (Rio J) 81:175–178

Brancaccio G, Toscano A, Bevilacqua M, Di Chiara L, Parisi F (2007) Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion? Pediatr Transplant 11:110–112PubMedCrossRef

10.

Brun H, Holmstrom H, Thaulow E (2005) Sudden death during a change in treatment for pulmonary hypertension. Cardiol Young 15:223–225PubMedCrossRef

11.

Burgess G, Hoogkamer H, Collings L, Dingemanse J (2008) Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 64:43–50PubMedCrossRef

12.

Carroll WD, Dhillon R (2003) Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 88:827–828PubMedCrossRef

13.

Celermajer DS, Cullen S, Deanfield JE (1993) Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 87:440–446PubMed

14.

Chaudhari M, Vogel M, Wright C, Smith J, Haworth SG (2005) Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy. Arch Dis Child Fetal Neonatal Ed 90:F527–F528PubMedCrossRef

15.

Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70–75PubMed

16.

Croom KF, Curran MP, Abman SH, Channick RN, Heresi GA, Rubin LJ, Torbicki A (2008) Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68:383–397PubMedCrossRef

17.

D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT et al (1991) Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115:343–349PubMed

18.

De Luca D, Zecca E, Vento G, De Carolis MP, Romagnoli C (2006) Transient effect of epoprostenol and sildenafil combined with iNO for pulmonary hypertension in congenital diaphragmatic hernia. Paediatr Anaesth 16:597–598PubMedCrossRef

19.

du Plessis FA, Helbing WA, Bogers AJ (2007) Excision of the tricuspid valve in a baby with Candida endocarditis. Cardiol Young 17:545–547PubMedCrossRef

20.

Filan PM, McDougall PN, Shekerdemian LS (2006) Combination pharmacotherapy for severe neonatal pulmonary hypertension. J Paediatr Child Health 42:219–220PubMedCrossRef

21.

Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148–2157PubMedCrossRef

22.

Gamboa D, Robbins D, Saba Z (2007) Bleeding after circumcision in a newborn receiving sildenafil. Clin Pediatr (Phila) 46:842–843CrossRef

23.

Garg N, Sharma MK, Sinha N (2007) Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol 120:306–313PubMedCrossRef

24.

Garg P (2008) Oral sildenafil for PPHN in neonates: selection of patients remains a dilemma? J Coll Physicians Surg Pak 18:132–133PubMed

25.

Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522PubMed

26.

Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q (1993) Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341:1550–1554PubMedCrossRef

27.

Giaid A, Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333:214–221PubMedCrossRef

28.

Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S (2005) Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 96:1334–1336PubMedCrossRef

29.

Hamdan MA, Abu-Sulaiman RM, Najm HK (2006) Sildenafil in pulmonary hypertension secondary to unilateral agenesis of pulmonary artery. Pediatr Cardiol 27:279–281PubMedCrossRef

30.

Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S (2006) Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 132:1232–1233PubMedCrossRef

31.

Haworth SG, Hislop AA (2009) Treatment and survival in children with pulmonary arterial hypertension: the UK pulmonary hypertension service for children 2001–2006. Heart 95:312–317PubMedCrossRef

32.

Higenbottam T, Wheeldon D, Wells F, Wallwork J (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1:1046–1047PubMedCrossRef

33.

Hoeper MM, Galie N, Simonneau G, Rubin LJ (2002) New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1209–1216PubMedCrossRef

34.

Hrometz SL, Shields KM (2006) Sildenafil citrate for the treatment of pulmonary hypertension. Drugs Today (Barc) 42:771–784CrossRef

35.

Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425–1436PubMedCrossRef

36.

Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111:3274–3280PubMedCrossRef

37.

Juliana AE, Abbad FC (2005) Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J Pediatr 164:626–629PubMedCrossRef

38.

Karatza AA, Narang I, Rosenthal M, Bush A, Magee AG (2004) Treatment of primary pulmonary hypertension with oral sildenafil. Respiration 71:192–194PubMedCrossRef

39.

Karatza AA, Bush A, Magee AG (2005) Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 100:267–273PubMedCrossRef

40.

Kawano H, Sengyoku H, Satoh O, Urabe S, Koide Y, Yano K (2007) Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate. Intern Med 46:893–898PubMedCrossRef

41.

Kecskes Z, Kent A, Reynolds G (2006) Treatment of pulmonary hypertension with sildenafil in a neonate with spondyloepiphyseal dysplasia congenita. J Matern Fetal Neonatal Med 19:579–582PubMedCrossRef

42.

Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S (2004) Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 5:184–187PubMedCrossRef

43.

Klinger JR (2007) The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 28:143–167; ixPubMedCrossRef

44.

Knoderer CA, Ebenroth ES, Brown JW (2005) Chronic outpatient sildenafil therapy for pulmonary hypertension in a child after cardiac surgery. Pediatr Cardiol 26:859–861PubMedCrossRef

45.

Kothari SS, Duggal B (2002) Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 54:404–409PubMed

46.

Kovacikova L, Zahorec M, Nosal M (2007) Sildenafil as a pulmonary vasodilator after repair of congenital heart disease. Bratisl Lek Listy 108:453–454PubMed

47.

Kulkarni A, Singh TP, Sarnaik A, Walters HL, Delius R (2004) Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant 23:1441–1444PubMedCrossRef

48.

Lammers AE, Haworth SG, Pierce CM (2006) Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. Cardiol Young 16:84–86PubMedCrossRef

49.

Lee JE, Hillier SC, Knoderer CA (2008) Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 23:329–334PubMedCrossRef

50.

LeGow B (ed) (2008) Drug Topics Red Book: pharmacy’s fundamental reference

51.

Leibovitch L, Matok I, Paret G (2007) Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs 67:57–73PubMedCrossRef

52.

Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Muhler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I (2006) First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 36(Suppl 3):32–38PubMedCrossRef

53.

Marsh CS, Marden B, Newsom R (2004) Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol 88:306–307PubMedCrossRef

54.

Mersal A, Attili I, Alkhotani A (2007) Severe neonatal pulmonary hypertension secondary to antenatal maternal diclofenac ingestion reversed by inhaled nitric oxide and oral sildenafil. Ann Saudi Med 27:448–449PubMedCrossRef

55.

Mourani PM, Sontag MK, Ivy DD, Abman SH (2009) Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 154:379–384CrossRefPubMed

56.

Mychaskiw G, Sachdev V, Heath BJ (2001) Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 13:218–220PubMedCrossRef

57.

Nahata MC, Morosco RS, Brady MT (2006) Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm 63:254–257PubMedCrossRef

58.

Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042–1047PubMedCrossRef

59.

Oliveira EC, Amaral CF (2005) Sildenafil in the management of idiopathic pulmonary arterial hypertension in children and adolescents. J Pediatr (Rio J) 81:390–394CrossRef

60.

Otero Gonzalez I, Blanco Aparicio M, Souto Alonso A, Raposo Sonnenfeld I, Verea Hernando H (2007) Clinical efficacy of sildenafil in patients with pulmonary hypertension in functional class II or III. Arch Bronconeumol 43:272–276PubMed

61.

Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR (2005) Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 60:107–112PubMedCrossRef

62.

Peiravian F, Amirghofran AA, Borzouee M, Ajami GH, Sabri MR, Kolaee S (2007) Oral sildenafil to control pulmonary hypertension after congenital heart surgery. Asian Cardiovasc Thorac Ann 15:113–117PubMed

63.

Raposo-Sonnenfeld I, Otero-Gonzalez I, Blanco-Aparicio M, Ferrer-Barba A, Medrano-Lopez C (2007) Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger’s syndrome. Rev Esp Cardiol 60:366–372PubMedCrossRef

64.

Revatio [package insert]. Phizer, New York, 2007

65.

Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81PubMed

66.

Romberg E (1891) Uebersklerose der lungen arterie. Dsch Arch Klin Med 48:197–206

67.

Rosenzweig EB, Widlitz AC, Barst RJ (2004) Pulmonary arterial hypertension in children. Pediatr Pulmonol 38:2–22PubMedCrossRef

68.

Ruiz MJ, Escribano P, Delgado JF, Jimenez C, Tello R, Gomez MA, de la Calzada CS (2006) Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J Heart Lung Transplant 25:1353–1357PubMedCrossRef

69.

Sastry BK, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR, Kumar DN (2002) A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 54:410–414PubMed

70.

Saygili A, Canter B, Iriz E, Kula S, Tunaoglu FS, Olgunturk R, Ozdogan ME (2004) Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension. J Cardiothorac Vasc Anesth 18:775–776PubMedCrossRef

71.

Schulze-Neick I, Li J, Penny DJ, Redington AN (2001) Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg 121:1033–1039PubMedCrossRef

72.

Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hubler M, Butrous G, Petros A, Lange P, Redington AN (2003) Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108(Suppl 1):II167–III173PubMed

73.

Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12SPubMedCrossRef

74.

Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521–530PubMed

75.

Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006) A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151(851):e851–e855

76.

Sivaswamy L, Vanstavern GP (2007) Ischemic optic neuropathy in a child. Pediatr Neurol 37:371–372PubMedCrossRef

77.

Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS (2003) Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 29:1996–2003PubMedCrossRef

78.

Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA (2008) Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 21:824–832PubMedCrossRef

79.

Wanstall JC, Jeffery TK (1998) Recognition and management of pulmonary hypertension. Drugs 56:989–1007PubMedCrossRef

80.

Wessel DL (1993) Inhaled nitric oxide for the treatment of pulmonary hypertension before and after cardiopulmonary bypass. Crit Care Med 21:S344–S345PubMedCrossRef

81.

Widlitz A, Barst RJ (2003) Pulmonary arterial hypertension in children. Eur Respir J 21:155–176PubMedCrossRef

82.

Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS (2006) Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J Paediatr Child Health 42:147–148PubMedCrossRef

Titel: Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients
verfasst von: Alice J. Huddleston
Chad A. Knoderer
Jennifer L. Morris
Eric S. Ebenroth
Publikationsdatum: 01.10.2009
Verlag: Springer-Verlag
Erschienen in: Pediatric Cardiology / Ausgabe 7/2009
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-009-9523-1

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients

Abstract

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

Closure of a Superior Vena Cava Baffle Leak in a Patient with D-Transposition After Mustard Palliation: Importance of Both Angiography and Echocardiography for Confirmation of Closure

Hypoxia-Induced Cytosolic Calcium Decrease Is Mediated Primarily by the Forward Mode of Na+/Ca2+ Exchanger in Smooth Muscle Cells of Fetal Ductus Arteriosus

Left Ventricular Noncompaction: A Rare Cause of Hydrops Fetalis

Preserved Flow-Mediated Dilation in Adults with Cyanotic Congenital Heart Disease

Case Report by Awad and Coworkers

Comparison of S100B and NSE Between Cardiac Surgery and Interventional Therapy for Children

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie